What Happened
- India launched a nationwide free HPV vaccination programme on 28 February 2026, targeting girls aged 9–14 with a single dose of HPV vaccine, tracked via the U-WIN digital platform.
- The programme has chosen Gardasil 4 (by Merck) as the primary vaccine, sidelining Cervavac — India's indigenously developed HPV vaccine by the Serum Institute of India (SII).
- The reason: Gardasil has established single-dose immunogenicity data, while Cervavac's single-dose equivalence is still being tested in an ongoing ICMR-led immunobridging study.
- The ICMR study is comparing whether a single dose of Cervavac generates protective antibodies equivalent to a single dose of Gardasil — a prerequisite for Cervavac to join the national programme on a single-dose schedule.
- Once Cervavac's single-dose data clears the ICMR study, it is expected to be included in the campaign.
- The irony: Cervavac was developed specifically to serve India's public health needs at lower cost, yet the government's urgency to launch — driven partly by political timing — has led to the programme starting without the indigenous vaccine.
Static Topic Bridges
Human Papillomavirus (HPV) and Cervical Cancer
Human papillomavirus (HPV) is a sexually transmitted virus responsible for nearly all cases of cervical cancer. Over 200 strains of HPV exist; types 16 and 18 account for approximately 70% of cervical cancers globally and 76.7% in India. HPV also causes other anogenital cancers and oropharyngeal cancers.
- Cervical cancer is the second most common cancer among Indian women, with approximately 1.27 lakh new cases and 79,900 deaths annually (2022 data).
- India contributes over 65% of the cervical cancer burden in the WHO South-East Asia Region.
- India has approximately 36.5 crore women above 15 years at risk; only 1.9% of women aged 30–49 undergo cervical cancer screening.
- HPV vaccines are most effective when given before sexual debut, hence the 9–14 age group is the primary target.
- WHO's 90-70-90 target by 2030: 90% of girls fully vaccinated by age 15, 70% of women screened, 90% of women with disease treated.
Connection to this news: The nationwide HPV vaccination programme is a major step toward reducing India's cervical cancer burden. The choice of vaccine — Gardasil vs. Cervavac — has consequences for both cost-effectiveness and the long-term sustainability of the programme.
Cervavac — India's Indigenous HPV Vaccine
Cervavac is India's first indigenous HPV vaccine, developed by the Serum Institute of India (SII) in Pune. It is a quadrivalent vaccine targeting HPV types 6, 11, 16, and 18 — the same strains covered by Gardasil 4.
- Clinical trials published in The Lancet showed Cervavac to be non-inferior to Gardasil in girls and boys aged 9–14, with comparable immune responses and safety profiles.
- Cervavac is significantly cheaper than Gardasil — priced for the public market at substantially lower cost, making it more viable for large-scale national programmes.
- It received DCGI approval in 2022, making India only the second country (after the US) to produce its own HPV vaccine.
- Two-dose data for Cervavac is well-established; the ongoing ICMR study focuses on single-dose non-inferiority.
Connection to this news: The exclusion of Cervavac from the initial phase of the national programme undermines the "Make in India" logic of vaccine development — the vaccine was developed precisely to serve India's public health needs at accessible cost, yet procedural gaps (incomplete single-dose data) have delayed its inclusion.
Universal Immunisation Programme (UIP) and Vaccine Introduction Policy
India's Universal Immunisation Programme (UIP) is one of the largest public health programmes in the world, covering 12 antigens across all districts. New vaccines are introduced into the UIP based on recommendations from the National Technical Advisory Group on Immunisation (NTAGI), supported by evidence of safety, immunogenicity, and cost-effectiveness.
- HPV vaccine was recommended for national introduction by NTAGI; it was previously offered only in school-based pilot programmes in select states.
- India's U-WIN platform (Universal Immunisation with Digital Tracking) is the digital backbone for tracking vaccine doses, replacing paper registers.
- The shift from multi-dose to single-dose schedules for HPV significantly reduces logistical burden — a key consideration for India's vast immunisation infrastructure.
- Pentavalent vaccine, rotavirus vaccine, and pneumococcal vaccine were introduced into UIP in recent years as precedents for new vaccine additions.
Connection to this news: The ICMR immunobridging study for Cervavac is following standard NTAGI/WHO protocols for single-dose evidence generation. Until the study concludes, Cervavac cannot formally meet the single-dose programme's evidence threshold, regardless of its two-dose track record.
Make in India in Pharmaceuticals — Ambitions and Bottlenecks
India is the world's pharmacy — the largest supplier of generic medicines and a significant producer of vaccines. The government's "Make in India" initiative in pharmaceuticals aims to increase indigenous production, reduce import dependence, and position Indian companies as global suppliers.
- Serum Institute of India is the world's largest vaccine manufacturer by volume, producing more than 1.5 billion doses annually.
- India supplied approximately 60% of global vaccine demand in pre-COVID years.
- The Atmanirbhar Bharat push accelerated domestic vaccine development — Covaxin (Bharat Biotech) and Cervavac (SII) are prominent outcomes.
- Despite manufacturing strength, regulatory data requirements (especially for new dosing schedules) can create gaps between product approval and public programme inclusion.
Connection to this news: Cervavac's sidelining illustrates that "Make in India" in vaccines requires not just manufacturing capability but also generating complete regulatory evidence for every intended deployment scenario — a lesson for future indigenisation efforts.
Key Facts & Data
- India's nationwide HPV vaccination programme launched: 28 February 2026.
- Target group: Girls aged 9–14; single-dose schedule; tracked via U-WIN platform.
- Vaccine chosen for Phase 1: Gardasil 4 (Merck).
- Indigenous alternative: Cervavac by Serum Institute of India (SII), quadrivalent, approved by DCGI in 2022.
- Ongoing study: ICMR immunobridging study — single dose Cervavac vs. single dose Gardasil for non-inferiority.
- Cervical cancer burden: ~1.27 lakh new cases and ~79,900 deaths annually in India (2022).
- HPV types 16 and 18 account for 76.7% of cervical cancer in India.
- India has ~3.65 crore (365 million) women above 15 years at risk of cervical cancer.
- National cervical cancer screening coverage: only 1.9% of women aged 30–49.
- WHO 90-70-90 target: 90% of girls vaccinated by age 15 by 2030 — India is a signatory.